Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
Lancet
    December 2026
  1. ARUNDEL C, Mandefield L, Fairhurst C, Gkekas A, et al
    The diabetic foot after SWHSI-2: healing is not one size fits all - Authors' reply.
    Lancet. 2026;406:2925-2926.
    >> Share

  2. VAS P, Chong P
    The diabetic foot after SWHSI-2: healing is not one size fits all.
    Lancet. 2026;406:2924-2925.
    >> Share

  3. CHOW EW, Chow E
    Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity.
    Lancet. 2026;406:2866-2868.
    >> Share

  4. MUSKIET MHA, Nardone M, Rensen PCN, Cherney DZI, et al
    Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
    Lancet. 2026;406:2980-2983.
    >> Share

    July 2026
  5. MORA P, Aroda VR, Asong M, Bluher M, et al
    Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
    Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248.
    >> Share

  6. MORA P, Aroda VR, Asong M, Bluher M, et al
    Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
    Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247.
    >> Share

  7. KIRBY T
    Anette Ziegler: breaking through boundaries in type 1 diabetes.
    Lancet. 2026;408:205.
    >> Share

    June 2026
  8. KHUNTI K, Zaccardi F, Mehta R, Gregg EW, et al
    Epidemiology of cardiometabolic multiple long-term conditions.
    Lancet. 2026;407:2641-2654.
    >> Share

  9. BAJAJ HS, Welch M, Shah P, Luna E, et al
    Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
    Lancet. 2026;407:2402-2413.
    >> Share

  10. ORTIZ A, Fernandez-Fernandez B
    Finerenone: kidney protection beyond type 2 diabetes.
    Lancet. 2026;407:2348-2350.
    >> Share

  11. ARODA VR, Davies MJ, Maaske J, Millegard M, et al
    Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
    Lancet. 2026 Jun 8:S0140-6736(26)00802-0. doi: 10.1016/S0140-6736(26)00802.
    >> Share

  12. WELCH M, Forst T, Jia W, Del Pino PO, et al
    Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
    Lancet. 2026 Jun 8:S0140-6736(26)00800-7. doi: 10.1016/S0140-6736(26)00800.
    >> Share

  13. DAVIES MJ, Aroda VR, Rosenstock J, Capehorn M, et al
    Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
    Lancet. 2026 Jun 8:S0140-6736(26)00748-8. doi: 10.1016/S0140-6736(26)00748.
    >> Share

  14. VAN RAALTE DH, Muskiet MHA
    Beyond insulin escalation: REIMAGINE 3 and advanced type 2 diabetes care.
    Lancet. 2026 Jun 7:S0140-6736(26)01074-3. doi: 10.1016/S0140-6736(26)01074.
    >> Share

  15. ROSENSTOCK J, Billings LK, Gajria R, Giorgino F, et al
    Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
    Lancet. 2026 Jun 7:S0140-6736(26)01022-6. doi: 10.1016/S0140-6736(26)01022.
    >> Share

    March 2026
  16. KASUJJA FX, Aikaeli F, Garrib A, van Widenfelt E, et al
    Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.
    Lancet. 2026;407:1084-1094.
    >> Share

    February 2026
  17. ROSENSTOCK J, Yabe D, Cox D, Li J, et al
    Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
    Lancet. 2026 Feb 26:S0140-6736(26)00202-3. doi: 10.1016/S0140-6736(26)00202.
    >> Share

  18. BONACA MP, Nordanstig J, Ludvik B, Videmark A, et al
    Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes - Authors' reply.
    Lancet. 2026;407:573-574.
    >> Share

  19. ALNIMA T, Smits MM
    Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes.
    Lancet. 2026;407:573.
    >> Share

  20. GROARKE EM, Turturice B, Patel BA, Quinn KA, et al
    VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
    Lancet. 2026;407:637-648.
    >> Share

    January 2026
  21. NAUCK MA, Tuttle KR, Tschop MH, Bluher M, et al
    Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
    Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105.
    >> Share

  22. ABIZAID A, Mehran R, Oliva A, Chamie D, et al
    Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
    Lancet. 2026 Jan 8:S0140-6736(25)02157-9. doi: 10.1016/S0140-6736(25)02157.
    >> Share

    November 2025
  23. HORN DB, Ryan DH, Kis SG, Alves B, et al
    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
    Lancet. 2025 Nov 20:S0140-6736(25)02165-8. doi: 10.1016/S0140-6736(25)02165.
    >> Share

  24. ROEP BO
    Personalised prevention therapy in type 1 diabetes.
    Lancet. 2025 Nov 11:S0140-6736(25)02005-7. doi: 10.1016/S0140-6736(25)02005.
    >> Share

  25. ZIEGLER AG, Achenbach P, Weiss A, Berner R, et al
    Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
    Lancet. 2025 Nov 11:S0140-6736(25)01726-X. doi: 10.1016/S0140-6736(25)01726.
    >> Share

  26. HEERSPINK HJL, Cardona JF, Jolly S, Pergola PE, et al
    Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
    Lancet. 2025 Nov 8:S0140-6736(25)02014-8. doi: 10.1016/S0140-6736(25)02014.
    >> Share

    September 2025
  27. ZIEGLER AG, Cengiz E, Kay TWH
    The future of type 1 diabetes therapy.
    Lancet. 2025 Sep 19:S0140-6736(25)01438-2. doi: 10.1016/S0140-6736(25)01438.
    >> Share

  28. ISGANAITIS E, Laffel LM
    Dual incretin agonist for paediatric type 2 diabetes: an eagerly awaited opportunity.
    Lancet. 2025 Sep 19:S0140-6736(25)01908-7. doi: 10.1016/S0140-6736(25)01908.
    >> Share

  29. SPEAKE C
    ATG as disease-modifying therapy for new-onset type 1 diabetes.
    Lancet. 2025 Sep 18:S0140-6736(25)01773-8. doi: 10.1016/S0140-6736(25)01773.
    >> Share

  30. MATHIEU C, Wych J, Hendriks AEJ, Van Ryckeghem L, et al
    Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
    Lancet. 2025 Sep 18:S0140-6736(25)01674-5. doi: 10.1016/S0140-6736(25)01674.
    >> Share

  31. HANNON TS, Chao LC, Barrientos-Perez M, Pamidipati KC, et al
    Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2025 Sep 17:S0140-6736(25)01774-X. doi: 10.1016/S0140-6736(25)01774.
    >> Share

    July 2025
  32. ZHOU B, Gregg EW, Danaei G, Ezzati M, et al
    Worldwide trends in diabetes prevalence: the NCD-RisC study - Authors' reply.
    Lancet. 2025;406:133-134.
    >> Share

  33. LIPSCOMBE L, Dasgupta K, Shah B
    Worldwide trends in diabetes prevalence: the NCD-RisC study.
    Lancet. 2025;406:132-133.
    >> Share

  34. BOYKO EJ, Ong KL, Duncan BB
    Worldwide trends in diabetes prevalence: the NCD-RisC study.
    Lancet. 2025;406:131-132.
    >> Share

  35. RUSSELL-JONES D, Klonoff DC
    Use of once-weekly insulins for type 1 diabetes.
    Lancet. 2025;406:130.
    >> Share

  36. LOVE KM, Kinlaw AC, Brown SA
    Use of once-weekly insulins for type 1 diabetes - Author's reply.
    Lancet. 2025;406:130-131.
    >> Share

  37. GASIOREK A, Heydorn A, Gabery S, Hjerpsted JB, et al
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025;406:135-148.
    >> Share

    June 2025
  38. MISRA S, Khunti K, Goyal A, Gable D, et al
    Managing early-onset type 2 diabetes in the individual and at the population level.
    Lancet. 2025 Jun 20:S0140-6736(25)01067-0. doi: 10.1016/S0140-6736(25)01067.
    >> Share

  39. LIM LL, Jones S, Cikomola JC, Hivert MF, et al
    Understanding the drivers and consequences of early-onset type 2 diabetes.
    Lancet. 2025 Jun 20:S0140-6736(25)01012-8. doi: 10.1016/S0140-6736(25)01012.
    >> Share

  40. LUK A, Wild SH, Jones S, Anjana RM, et al
    Early-onset type 2 diabetes: the next major diabetes transition.
    Lancet. 2025 Jun 20:S0140-6736(25)00830-X. doi: 10.1016/S0140-6736(25)00830.
    >> Share

  41. THE LANCET
    Early-onset type 2 diabetes: no time for defeatism.
    Lancet. 2025 Jun 20:S0140-6736(25)01295-4. doi: 10.1016/S0140-6736(25)01295.
    >> Share

  42. BLEVINS T, Dahl D, Perez Manghi FC, Murthy S, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.
    Lancet. 2025 Jun 20:S0140-6736(25)01069-4. doi: 10.1016/S0140-6736(25)01069.
    >> Share

  43. PHILIS-TSIMIKAS A, Bergenstal RM, Bailey TS, Jinnouchi H, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.
    Lancet. 2025 Jun 20:S0140-6736(25)01044-X. doi: 10.1016/S0140-6736(25)01044.
    >> Share

  44. CHOW EW, Chow E
    Future of once-weekly insulins in type 2 diabetes: efficacy and safety.
    Lancet. 2025 Jun 20:S0140-6736(25)01098-0. doi: 10.1016/S0140-6736(25)01098.
    >> Share

    May 2025
  45. GARDOSI J, Ewington LJ, Booth K, Bick D, et al
    Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.
    Lancet. 2025 May 1:S0140-6736(25)00162-X. doi: 10.1016/S0140-6736(25)00162.
    >> Share

    March 2025
  46. BONACA MP, Catarig AM, Houlind K, Ludvik B, et al
    Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00509-4. doi: 10.1016/S0140-6736(25)00509.
    >> Share

  47. DENNIS JM, Young KG, Cardoso P, Gudemann LM, et al
    A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
    Lancet. 2025;405:701-714.
    >> Share

  48. SEIDU S, Ikhile D
    Personalised type 2 diabetes therapy in primary care.
    Lancet. 2025;405:672-674.
    >> Share

    January 2025
  49. ADLER AI, Coleman RL, Whiteley WN, Holman RR, et al
    The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.
    Lancet. 2025;405:29.
    >> Share

  50. HOU R, Ren J
    The legacy effect of hyperglycaemia in type 2 diabetes.
    Lancet. 2025;405:28-29.
    >> Share

  51. PRATTICHIZZO F, Ceriello A
    The legacy effect of hyperglycaemia in type 2 diabetes.
    Lancet. 2025;405:28.
    >> Share

    November 2024

  52. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants.
    Lancet. 2024;404:2077-93.
    >> Share

  53. GUARIGUATA L, Sobers N
    Rising diabetes, lagging treatment, and the need for better systems.
    Lancet. 2024 Nov 12:S0140-6736(24)02422-X. doi: 10.1016/S0140-6736(24)02422.
    >> Share

    September 2024
  54. LOVE KM, Brown SA
    The promise of once-weekly insulins for type 1 diabetes: update on progress.
    Lancet. 2024;404:1081-1083.
    >> Share

  55. BERGENSTAL RM, Weinstock RS, Mathieu C, Onishi Y, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
    Lancet. 2024;404:1132-1142.
    >> Share

    August 2024
  56. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    >> Share

  57. DELLGREN JL, Persad G, Emanuel EJ
    International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches.
    Lancet. 2024 Aug 16:S0140-6736(24)01356-4. doi: 10.1016/S0140-6736(24)01356.
    >> Share

  58. MARECEK R, Kissling S, Teso AD, Vuignier Y, et al
    Chronic metabolic acidosis in a patient with diabetes on maintenance haemodialysis: mind the anion gap.
    Lancet. 2024;404:570-571.
    >> Share

    July 2024
  59. RODRIGUEZ-GUTIERREZ R
    Legacy effect of intensive glycaemic control in type 2 diabetes-the UKPDS.
    Lancet. 2024;404:100-102.
    >> Share

  60. SIMMONS D, Gupta Y, Hernandez TL, Levitt N, et al
    Call to action for a life course approach.
    Lancet. 2024;404:193-214.
    >> Share

    June 2024
  61. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    >> Share

  62. STRASSBURGER MATZENBACHER L, Alessi J, Telo GH
    Diabetes management amidst floods in Brazil.
    Lancet. 2024 Jun 26:S0140-6736(24)01177-2. doi: 10.1016/S0140-6736(24)01177.
    >> Share

  63. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    >> Share

  64. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    >> Share

    May 2024
  65. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    >> Share

  66. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    >> Share

  67. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    >> Share

  68. ADLER AI, Coleman RL, Leal J, Whiteley WN, et al
    Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
    Lancet. 2024 May 17:S0140-6736(24)00537-3. doi: 10.1016/S0140-6736(24)00537.
    >> Share

    March 2024
  69. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    >> Share

  70. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016